http://www.acc.org/Feed?clinicalTopicID=4ea474ce-5bda-4828-b03f-e99d73bea0c5 Clinical Topic Feed: Interventions and Structural Heart Disease en /Latest-in-Cardiology/Articles/2026/07/15/17/40/ACC-SCAI-and-STS-Submit-Feedback-on-Proposed-TAVR-NCD The ACC, along with the Society for Cardiovascular Angiography & Interventions (SCAI) and the Society of Thoracic Surgeons (STS), submitted formal comments to the Centers for Medicare and Medicaid Services (CMS) on July 15 regarding the proposed decision memo for the National Coverage Determination (NCD) for TAVR. 1784138100000 Articles and Stories /Latest-in-Cardiology/Articles/2026/07/15/14/19/eagles-eye-view-15jul2026 In this week’s View, Dr. Eagle looks at the feasibility of mechanical leaflet splitting in high-risk patients undergoing valve-in-valve transcatheter aortic valve replacement (TAVR). 1784125200000 Articles and Stories /Latest-in-Cardiology/Articles/2026/07/01/12/47/eagles-eye-view-01jul2026 In this week’s View, Dr. Eagle looks at how genotype independently predicts heart failure outcomes in patients with hypertrophic cardiomyopathy (HCM). 1782910140000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/06/29/15/38/PARTNER-3 TAVR and surgery demonstrated comparable and sustained valve durability in low-risk patients with symptomatic severe aortic stenosis (AS), with both approaches showing low and similar rates of structural valve deterioration (SVD), all-cause bioprosthetic valve failure (BVF) and reintervention through seven years... 1782845400000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/06/23/13/25/PARTNER-2A-P2S3i-Registry The rates of mortality and reintervention at 10 years were higher in patients at intermediate risk who underwent TAVR with the second-generation SAPIEN XT valve than those who underwent surgery in the PARTNER 2A trial, according to an analysis published June 16 in a valvular heart disease focus issue of JACC. 1782399420000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/06/23/13/25/Genotype-Independently-Predicts-HF-Outcomes In patients with hypertrophic cardiomyopathy (HCM), genotype, peak VO2, log NT-proBNP and LVEF independently predict heart failure (HF) outcomes, and combining these measures identified patients at higher risk of HF-related death or transplant, according to a recent study published in JACC: Heart Failure. 1782228900000 Articles and Stories /Latest-in-Cardiology/Articles/2026/06/17/17/38/CMS-Proposes-Updates-to-TAVR-National-Coverage-Determination The Centers for Medicare and Medicaid Services (CMS) released a proposed decision memo on the National Coverage Determination (NCD) for TAVR, introducing changes to coverage pathways, evidence development and quality oversight. 1781718060000 Articles and Stories /Latest-in-Cardiology/Articles/2026/06/16/16/01/eagles-eye-view-17jun2026 In this week’s View, Dr. Eagle highlights a study showing race and sex disparities in M-TEER outcomes, with Black patients presenting with more advanced disease, lower success, and higher heart failure readmissions than White patients, and women having lower success rates than men. 1781701440000 Articles and Stories /Latest-in-Cardiology/Articles/2026/06/01/01/Cover-Story-Tricuspid-Valve-Intervention For decades, cardiologists have referred to the tricuspid valve as "the forgotten valve." One reason for this neglect is that tricuspid regurgitation (TR) often goes unnoticed, explains Robert O. Bonow, MD, MACC, Distinguished Professor at Northwestern University Feinberg School of Medicine in Chicago, IL. 1780316340000 Articles and Stories /Latest-in-Cardiology/Articles/2026/06/01/01/Feature-Navigating-Valve-Disease Shared decision-making has become central to the management of valve disease, including tricuspid regurgitation (TR) (see cover story) and severe aortic stenosis (AS). If done correctly, it can help clinicians engage patients and families in meaningful discussions about symptoms, prognosis, treatment burden and personal goals... 1780316280000 Articles and Stories